Neurolixis is building a drug discovery and development pipeline:

Development of early-stage clinical assets:

Neurolixis is developing clinical-stage drugs targeted at serious CNS diseases with unmet medical needs and sizeable market opportunity.

NLX-112, is a Phase II-ready drug intended for the treatment of L-DOPA-induced dyskinesia, a side-effect of Parkinson's disease treatment.

NLX-101, is a Phase I drug intended for the treatment of breathing difficulties in Rett's syndrome, a genetically-encoded orphan disorder.


Synthesis and development of Novel Chemical Entities (NCEs):

Neurolixis' is exploring validated, but underexploited, pharmacological targets for NCEs, including serotonin and glutamate receptors. New mechanisms of action will be favored, with a focus on "biased agonism".


All drugs or therapies will be subjected to rigorous testing under applicable law and approval by regulatory authorities, including the FDA, prior to marketing and sale.


Please enable the javascript to submit this form

Follow Neurolixis on: